DURECT Newswire

DURECT Newswire

Comprehensive Real-Time News Feed for DURECT.

Results 1 - 20 of 68 in DURECT

  1. Here's What The Latest Pain Therapeutics, Inc. (PTIE) Update MeansRead the original story w/Photo

    Tuesday Feb 21 | Insider Monkey

    ... well worth catching up on for anyone considering an allocation to the drug going forward. In 2002, a company called DURECT Corporation (NASDAQ: DRRX ) licensed a technology called Oradur to Pain Therapeutics. Shortly after, Pain did a deal with the ...

    Comment?

  2. DURECT Announces Update On DUR-928 Development ProgramRead the original story

    Sunday Jan 29 | BioSpace

    /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today provided an update on the DUR-928 development program. DUR-928, our Epigenetic Regulator Program's lead product candidate, is an endogenous, small molecule, new chemical entity (NCE), which may ...

    Comment?

  3. Short Interest in DURECT Corporation (DRRX) Drops By 23.9%Read the original story

    Sunday Jan 29 | AmericanBankingNews.com

    DURECT Corporation was the target of a large decrease in short interest during the month of January. As of January 13th, there was short interest totalling 2,143,650 shares, a decrease of 23.9% from the December 30th total of 2,816,491 shares.

    Comment?

  4. DURECT Corporation (DRRX) Given Average Rating of "Buy" by AnalystsRead the original story w/Photo

    Jan 10, 2017 | IntersportsWire

    DURECT Corporation has received a consensus broker rating score of 2.00 from the two analysts that cover the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a hold recommendation and one has issued a strong buy recommendation on the company.

    Comment?

  5. Analysts Anticipate DURECT Corporation (DRRX) to Post ($0.07) Earnings Per ShareRead the original story w/Photo

    Jan 3, 2017 | AmericanBankingNews.com

    Shares of DURECT Corporation have earned a consensus broker rating score of 2.00 from the two analysts that provide coverage for the company, Zacks Investment Research reports. One analyst has rated the stock with a hold recommendation and one has issued a strong buy recommendation on the company.

    Comment?

  6. Research Reports Coverage on Drug Makers Stocks -- Depomed, DURECT,...Read the original story w/Photo

    Dec 21, 2016 | PR Newswire

    ... industry as a whole. This morning, Stock-Callers.com evaluates the following equities: Depomed Inc. (NASDAQ: DEPO ), DURECT Corp. (NASDAQ: DRRX ), United Therapeutics Corp. (NASDAQ: UTHR ), and Amphastar Pharmaceuticals Inc. (NASDAQ: AMPH ). These ...

    Comment?

  7. How DURECT Corporation (DRRX) Stacks Up Against Its PeersRead the original story w/Photo

    Dec 15, 2016 | Insider Monkey

    ... we analyze the activity of those successful funds in these small-cap stocks. In the following paragraphs, we analyze DURECT Corporation (NASDAQ: DRRX ) from the perspective of those successful funds. Is DURECT Corporation (NASDAQ:DRRX) a buy now? ...

    Comment?

  8. How Guidance Software, Inc. (GUID) Stacks Up Against Its PeersRead the original story w/Photo

    Dec 14, 2016 | Insider Monkey

    ... at the end of the previous quarter. At the end of this article we will also compare GUID to other stocks including DURECT Corporation (NASDAQ: DRRX ), Hallmark Financial Services, Inc. (NASDAQ: HALL ), and Deutsche Multi-Market Income Trust (NYSE: ...

    Comment?

  9. BRIEF-Positive trends seen with latest study of Biogen Alzheimer's drugRead the original story w/Photo

    Dec 8, 2016 | Reuters

    BRIEF-Pain Therapeutics says sent a letter to Durect pursuant to development and license agreement dated as of December 19, 2002 * Pain Therapeutics Inc says on Dec 5, co sent a letter to Durect Corp pursuant to development and license agreement dated as of December 19, 2002

    Comment?

  10. Broadfin Capital, LLC Maintains 6.1% Stake in Durect Corp.Read the original story w/Photo

    Nov 21, 2016 | Daily Political

    Broadfin Capital, LLC revealed that they own a 6.1% stake in Durect Corp. in a Schedule 13G disclosure that was filed with the Securities and Exchange Commission on Monday, November 21st. The investor owns 8,506,229 shares of the stock valued at $11,823,658.

    Comment?

  11. Durect Corporation Seeking More CollaborationsRead the original story w/Photo

    Nov 15, 2016 | Seeking Alpha

    With the REMOXY setback, Durect's near- and mid-term prospects hinge on two candidates for nonalcoholic steatohepatitis and pain. DUR-928 has multiple mechanisms of action that may prove to be of clinical benefit in NASH and could be an acquisition target.

    Comment?

  12. Schwab Charles Investment Management Inc. Has $217,000 Stake in Durect Corp.Read the original story w/Photo

    Nov 14, 2016 | Daily Political

    Schwab Charles Investment Management Inc. maintained its position in shares of Durect Corp. during the second quarter, Holdings Channel reports. The firm owned 177,776 shares of the specialty pharmaceutical company's stock at the end of the second quarter.

    Comment?

  13. Drug Makers Stocks on Investorsa Radar a " Amarin, Depomed, DURECT, and BiodelRead the original story w/Photo

    Nov 7, 2016 | Freshnews

    Last Friday, benchmark US indices extended their bearish trend as the NASDAQ Composite ended the trading session down 0.24%; the Dow Jones Industrial Average edged 0.24% lower; and the S&P 500 closed down 0.17%. As the US markets continue to perform mostly in red, stock-Callers.com this morning reviews these four Drug Makers' stocks: Amarin Corporation PLC , Depomed Inc. , DURECT Corporation , and Biodel Inc. .

    Comment?

  14. Drug Makers Stocks on Investors' Radar -- Amarin, Depomed, DURECT, and BiodelRead the original story w/Photo

    Nov 3, 2016 | PR Newswire

    Last Friday, benchmark US indices extended their bearish trend as the NASDAQ Composite ended the trading session down 0.24%; the Dow Jones Industrial Average edged 0.24% lower; and the S&P 500 closed down 0.17%. As the US markets continue to perform mostly in red, stock-Callers.com this morning reviews these four Drug Makers' stocks: Amarin Corporation PLC , Depomed Inc. , DURECT Corporation , and Biodel Inc. .

    Comment?

  15. Durect Corp. (DRRX) Major Shareholder April Fund L.P. 21 Buys 95,000 SharesRead the original story w/Photo

    Nov 4, 2016 | Daily Political

    Durect Corp. major shareholder April Fund L.P. 21 acquired 95,000 shares of the business's stock in a transaction dated Thursday, November 3rd. The stock was purchased at an average cost of $1.16 per share, with a total value of $110,200.00.

    Comment?

  16. The Life Sciences Report Examines Why the Election Is Not as Relevant ...Read the original story w/Photo

    Nov 3, 2016 | Market Wire

    ... last month) affords an excellent buying opportunity in select names with promising pipelines. In this group I include DURECT Corp. Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, ...

    Comment?

  17. Why the Election Is Not as Relevant to Drug Stocks as You Might BelieveRead the original story w/Photo

    Nov 3, 2016 | InvestorIdeas.com

    ... in pharmaceutical stocks affords an excellent buying opportunity in select names with promising pipelines, including DURECT Corp. " California's Proposition 61 would require state agencies to pay the same price as the U.S. Department of Veteran ...

    Comment?

  18. DURECT's (DRRX) CEO Jim Brown on Q3 2016 Results - Earnings Call TranscriptRead the original story w/Photo

    Oct 31, 2016 | Seeking Alpha

    Greetings, and welcome to the DURECT Third Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode.

    Comment?

  19. DURECT's DUR-928 shows encouraging activity in early-stage NASH study; shares up 16% after hoursRead the original story w/Photo

    Oct 31, 2016 | Seeking Alpha

    Micro cap DURECT is up 16% after hours on average volume in response to its announcement of promising data from the first cohort in a Phase 1b study assessing DUR-928 in patients with nonalcoholic steatohepatitis . The study is being conducted on successive cohorts evaluating single-dose levels of orally administered DUR-928.

    Comment?

  20. DURECT Corporation Announces Update on DUR-928 Development ProgramRead the original story w/Photo

    Oct 31, 2016 | Freshnews

    DURECT Corporation today provided an update on the DUR-928 development program including a description of data from the first cohort of a Phase 1b study with DUR-928 in patients with nonalcoholic steatohepatitis . "We are pleased to report data from cohort one of the first patient study with DUR-928, and that a single dose provided signals of DUR-928 activity in cirrhotic and non-cirrhotic NASH patients," stated James E. Brown, D.V.M., President and CEO of DURECT.

    Comment?